FN3 Protein Scaffolds With Alternative Binding Surfaces

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing monoclonal antibodies and conventional FN3 domain libraries face limitations in achieving high affinity and specificity for target molecules due to their structural constraints and limited binding surfaces.

Innovation Solution

The development of FN3 domain scaffolds with randomized concave interaction surfaces formed by alternative beta-strands and loops, allowing for increased diversity and affinity to target molecules through randomization of these surfaces.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional FN3 domain libraries use traditional loop randomization (FG, BC, DE loops), then binding specificity is improved, but binding affinity and diversity of targets are limited

Engineering Contradiction:
Improvebinding specificityVSAvoiddiversity of targets
Core Design Contradiction:
Measurement precisionVSAdaptability or versatility

Solution Approach 1:

The patent transitions from randomizing only loops to randomizing an alternative surface comprising both beta-strands and loops together. This dimensional expansion in the design space (from 1D loop sequences to 2D surface structures) enables access to novel binding modes and targets while maintaining specificity, directly resolving the contradiction between specificity and versatility.

Inventive Principle:
Principle #17Another dimension (Dimensionality change)

Solution Approach 2:

The patent changes the fundamental parameter of what is being randomized - shifting from loop-only randomization to alternative surface randomization that includes beta-strands. This parameter change expands the conformational and sequence space explored, enabling discovery of binders with both high specificity and broad target diversity simultaneously.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If monoclonal antibodies are used for high affinity binding, then binding affinity is improved, but structural stability and ease of expression are reduced

Engineering Contradiction:
Improvebinding affinityVSAvoidstructural stability
Core Design Contradiction:
ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent applies local quality by concentrating randomization efforts specifically on the alternative surface (beta-strands and loops) while keeping the rest of the FN3 domain structure fixed and stable. This localized approach enables high affinity binding through diversified binding surfaces while maintaining the overall structural stability and simplicity of the FN3 scaffold.

Inventive Principle:
Principle #3Local quality

3Adaptability or versatility

If extensive randomization is performed to increase diversity, then adaptability is improved, but structural stability may be compromised

Engineering Contradiction:
Improvelibrary diversityVSAvoidscaffold stability
Core Design Contradiction:
Adaptability or versatilityVSStability of the object's composition

Solution Approach 1:

The patent segments the FN3 domain into two functional regions: a stable core (the rest of the domain structure) and a diversified surface (the alternative surface with beta-strands and loops). By segmenting the randomization to only the surface region, the patent achieves high library diversity while preserving the structural stability of the core scaffold.

Inventive Principle:
Principle #1Segmentation

Data Source

PatentEP4151785B1Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces
Publication Date: 2026.01.28 JANSSEN BIOTECH INC
  • EP4151785B1 patent drawingFigure 1
  • EP4151785B1 patent drawingFigure 2A
  • EP4151785B1 patent drawingFigure 2B

AI summary

Protein scaffolds and scaffold libraries based on a fibronectin type III (FN3) repeat with an alternative binding surface design, isolated nucleic acids encoding the protein scaffolds, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.